Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (616)	11/7/2001 8:27:19 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

no mention of Axiom........... Wednesday November 7, 4:31 pm Eastern Time Press Release SOURCE: Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. Completes an Initial Human Tissue Mapping of G Protein-Coupled Receptors Localizes Over 700 GPCR Targets SAN DIEGO, Nov. 7 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news) announced today that it has completed its initial analysis of human G protein-coupled receptor (GPCR) gene expression in 80 normal human tissues. Utilizing a proprietary, custom-designed, oligonucleotide ``GPCR chip,'' Arena has identified relative expression levels of more than 700 GPCRs across these human tissues. Results indicate a large number of previously unidentified GPCRs are expressed in tissues that Arena believes are of high therapeutic importance, including over 225 receptors within major systems of the central nervous system, approximately 180 GPCRs localized to various cardiovascular tissues and approximately 300 receptors in endocrine/metabolic systems. The company is now extending its analysis to examine GPCR expression levels in a variety of human diseased tissues and biopsy samples with the aim of prioritizing GPCRs for small molecule drug discovery. ``These initial mapping studies are an important first step for Arena in helping us prioritize GPCRs for potential therapeutic value in each of our clinical areas of interest. In addition, this completes one of the first important milestones for Arena in Project Genesis well within schedule,'' stated Dr. Derek Chalmers, Vice President of Research. ``This chip is also designed to provide us with data related to a host of tissue-specific and disease markers as well as components of cellular signaling which we believe give us important functional clues related to this large number of receptors,'' he added. Arena will present analysis of GPCR expression within the human central nervous system on November 12 at the International Society for Neuroscience meeting in San Diego. Arena has initiated ``Project Genesis,'' an internal program aimed at obtaining all of the human GPCRs, identifying the location of these receptors within normal and diseased tissue of the human body for purposes of understanding the function of such receptors, and screening each GPCR to identify receptor modulators that form the basis of drug candidates. Arena's CART and Melanophore technologies allow for the direct identification of modulators of G protein-coupled receptors in a ligand-independent manner, making these technologies particularly useful with respect to the estimated 800 therapeutically relevant GPCRs in the human genome. Such ligand-independent screening is made possible by proprietary genetic alteration of these receptors. We believe our CART and Melanophore technologies will facilitate completion of Project Genesis within the next three to five years. Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward looking statements include statements about the importance of data we have obtained and statements that are not historical facts, including statements which are preceded by the words ``intends,'' ``will,'' ``plans,'' ``expects,'' ``anticipates,'' ``estimates,'' ``aims,'' and ``believes'' or similar words. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Important factors that could cause actual results to differ materially from those stated or implied by Arena's forward looking statements due to risks and uncertainties associated with Arena's business include, but are not limited to, the following: the ability to complete Project Genesis, if at all, within a reasonable time period; future quarterly or annual financial results; the timing, success and cost of preclinical research, out-licensing endeavors and clinical studies; and receipt of additional milestone payments, if any, from collaborators. Additional risk factors that could cause actual results to differ materially from those in Arena's forward looking statements are disclosed in Arena's SEC reports, including, but not limited to, Arena's registration statement filed June 21, 2001 on Form S-1, as amended, its most recent quarterly report on Form 10-Q and its most recent annual report on Form 10-K. These forward-looking statements represent Arena's judgment as of the date of this release. Arena disclaims, however, any intent or obligation to update these forward-looking statements. ``Arena Pharmaceuticals'' is a registered U.S. trademark of the company. ``Arena'' and ``CART'' are trademarks of the company. Arena's headquarters are located at 6166 Nancy Ridge Drive, San Diego, CA 92121. Arena's telephone number is (858) 453-7200. On the Internet, please refer to Arena's website: arenapharm.com or BRL Screening's website: brlscreening.com for further information regarding CART Technology and the Melanophore Technology. SOURCE: Arena Pharmaceuticals, Inc.